TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Antengene Corporation Limited ( (HK:6996) ) just unveiled an update.
Antengene Corporation Limited reported a 36.7% increase in revenue for the year ended December 31, 2024, driven by strong sales in Mainland China, despite a price reduction following the inclusion of XPOVIO® in the National Reimbursement Drug List. The company also achieved substantial cost reductions across research and development, selling and distribution, and administrative expenses, resulting in a decreased annual loss of RMB319.3 million, compared to RMB581.2 million in the previous year. This financial performance highlights Antengene’s improved operational efficiency and strategic market positioning.
More about Antengene Corporation Limited
Antengene Corporation Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative oncology therapies. The company primarily operates in the Asia-Pacific region, with a significant market focus on Mainland China.
YTD Price Performance: 530.0%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €257.3M
For a thorough assessment of 6996 stock, go to TipRanks’ Stock Analysis page.